Anti-Cytokine Therapeutics: History and Update

Author(s): Rojo A. Ratsimandresy, Jay Rappaport, Jean-Francois Zagury.

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 17 , 2009

Become EABM
Become Reviewer

Abstract:

Anti-cytokine therapy has promoted a revolution in the treatment of several inflammatory disorders during the past 10 years. Despite their medical and commercial success, they exhibit several drawbacks: difficulties of production, excessive costs, and a few side-effects. A promising alternative to the passive infusion of monoclonal antibodies or soluble cytokine receptors is the use of the active anti-cytokine immune therapy (ACIT). Surprisingly, clinical studies suggested the interest of this approach during the late 1980s, even before the advent of anti-cytokine passive immunotherapy. In this review, we first explain the involvement of several cytokines in many common diseases involving cytokine overproduction, and identify key targets for anti-cytokine treatments. We then present an update on current advances in preclinical and clinical development of passive anti-cytokine therapeutic approaches. We further discuss progresses in the promising field of active anti-cytokine immunotherapy. Cytokine receptors biologics and small molecules developed using structure/function information, which also constitute important options for treating the cytokine-mediated diseases, are not discussed in this review.

Keywords: Anti-cytokine therapy, asthma, autoimmunity, cancer, cytokines, diabetes, immune-mediated inflammatory disease, inflammatory bowel disease, multiple sclerosis, psoriasis

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 17
Year: 2009
Page: [1998 - 2025]
Pages: 28
DOI: 10.2174/138161209788453130
Price: $58

Article Metrics

PDF: 14